JUBILANT PHARMOVA Financial Statement Analysis
|
||
|
The Revenues of JUBILANT PHARMOVA have increased by 2.47% YoY .
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has increased by Positive YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
JUBILANT PHARMOVA Last 5 Annual Financial Results
[BOM: 530019|NSE : JUBLPHARMA]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹6,282 Cr | ₹6,130 Cr | ₹6,099 Cr | ₹5,976 Cr | ₹9,111 Cr |
| Expenses | ₹5,506 Cr | ₹4,974 Cr | ₹4,702 Cr | ₹4,428 Cr | ₹7,372 Cr |
| Operating Profit (Excl OI) | ₹776 Cr | ₹1,156 Cr | ₹1,396 Cr | ₹1,548 Cr | ₹1,739 Cr |
| Other Income | ₹38 Cr | ₹11 Cr | ₹18 Cr | ₹37 Cr | ₹36 Cr |
| Interest | ₹188 Cr | ₹145 Cr | ₹184 Cr | ₹200 Cr | ₹220 Cr |
| Depreciation | ₹554 Cr | ₹382 Cr | ₹349 Cr | ₹340 Cr | ₹371 Cr |
| Profit Before Tax | ₹28 Cr | ₹630 Cr | ₹871 Cr | ₹1,013 Cr | ₹904 Cr |
| Profit After Tax | ₹-65 Cr | ₹413 Cr | ₹574 Cr | ₹678 Cr | ₹577 Cr |
| Consolidated Net Profit | ₹-61 Cr | ₹414 Cr | ₹836 Cr | ₹898 Cr | ₹574 Cr |
| Earnings Per Share (Rs) | ₹4.88 | ₹-3.84 | ₹26.01 | ₹52.51 | ₹56.39 |
| PAT Margin (%) | 1.08 | -1.03 | 6.74 | 9.41 | 11.34 |
| ROE(%) | 1.34 | -1.21 | 8.21 | 11.09 | 13.02 |
| ROCE(%) | 5.02 | 2.53 | 9.97 | 12.02 | 12.20 |
| Total Debt/Equity(x) | 0.63 | 0.63 | 0.55 | 0.55 | 0.83 |
Key Financials |
||
| Market Cap | : | ₹ 14,639.7 Cr |
| Revenue (TTM) | : | ₹ 7,064.3 Cr |
| Net Profit(TTM) | : | ₹ 620.2 Cr |
| EPS (TTM) | : | ₹ 38.9 |
| P/E (TTM) | : | 23.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| JUBILANT PHARMOVA | 11% | 6.1% | 43.2% |
| SUN PHARMACEUTICAL INDUSTRIES | 6% | 4% | 9.9% |
| DIVIS LABORATORIES | 4.7% | 0.3% | 52.4% |
| CIPLA | 7% | 3.7% | 7.2% |
| TORRENT PHARMACEUTICALS | 4.1% | 6.4% | 25% |
| DR REDDYS LABORATORIES | 6.3% | 5% | -4.7% |
| MANKIND PHARMA | 11.6% | 17.3% | 8.8% |
| ZYDUS LIFESCIENCES | -1.6% | -5.8% | -14.5% |
| LUPIN | 0.8% | -1.6% | 19.3% |
JUBILANT PHARMOVA Revenues
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | 2.47 % |
| 5 Yr CAGR | -8.88 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹6,282 Cr | 2.47 | |
| Mar2023 | ₹6,130 Cr | 0.52 | |
| Mar2022 | ₹6,099 Cr | 2.05 | |
| Mar2021 | ₹5,976 Cr | -34.41 | |
| Mar2020 | ₹9,111 Cr | - | |
JUBILANT PHARMOVA Operating Profit
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | -32.87 % |
| 5 Yr CAGR | -18.26 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹776 Cr | -32.87 | |
| Mar2023 | ₹1,156 Cr | -17.20 | |
| Mar2022 | ₹1,396 Cr | -9.79 | |
| Mar2021 | ₹1,548 Cr | -10.99 | |
| Mar2020 | ₹1,739 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -34.46 % |
| 5 Yr CAGR | -10.30 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 12.36% | -34.46 | |
| Mar2023 | 18.86% | -17.64 | |
| Mar2022 | 22.9% | -11.58 | |
| Mar2021 | 25.9% | 35.67 | |
| Mar2020 | 19.09% | - | |
JUBILANT PHARMOVA Profit After Tax
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹-61 Cr | Negative | |
| Mar2023 | ₹414 Cr | -50.48 | |
| Mar2022 | ₹836 Cr | -6.94 | |
| Mar2021 | ₹898 Cr | 56.36 | |
| Mar2020 | ₹574 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | -44.45 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 1.08 % | Positive | |
| Mar2023 | -1.03 % | Negative | |
| Mar2022 | 6.74 % | -28.37 | |
| Mar2021 | 9.41 % | -17.02 | |
| Mar2020 | 11.34 % | - | |
JUBILANT PHARMOVA Earnings Per Share (EPS)
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | Positive |
| 5 Yr CAGR | -45.76 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹4.88 | Positive | |
| Mar2023 | ₹-3.84 | Negative | |
| Mar2022 | ₹26 | -50.47 | |
| Mar2021 | ₹53 | -6.88 | |
| Mar2020 | ₹56 | - | |
JUBILANT PHARMOVA Return on Capital Employed (ROCE)
[BOM: 530019|NSE : JUBLPHARMA]
| Y-o-Y | 98.42 % |
| 5 Yr CAGR | -19.91 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 5.02% | 98.42 | |
| Mar2023 | 2.53% | -74.62 | |
| Mar2022 | 9.97% | -17.05 | |
| Mar2021 | 12.02% | -1.48 | |
| Mar2020 | 12.2% | - | |
JUBILANT PHARMOVA Share Price vs Sensex
| Current Share Price | : | ₹919.0 |
| Current MarketCap | : | ₹ 14,639.7 Cr |
| Updated EOD on | : | Apr 17,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JUBILANT PHARMOVA | 11% |
6.1% |
43.2% |
| SENSEX | 5.8% |
6.1% |
4.7% |
JUBILANT PHARMOVA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE SMALLCAP | 6.7% | 8.7% | 3.9% |
| BSE ALLCAP | 6.5% | 5.3% | 2.7% |
| BSE 250 SMALLCAP INDEX | 6.3% | 8.2% | -0.6% |
| BSE MIDSMALLCAP | 6.1% | 7.7% | 3.1% |
| BSE 400 MIDSMALLCAP INDEX | 5.8% | 7.6% | 2.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY SMALLCAP 250 | 6.6% | 8.9% | 0.4% |
| NIFTY 500 EQUAL WEIGHT | 6.3% | 8% | NA |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | 6% | 7.7% | NA |
| NIFTY MIDSMALLCAP 400 | 6% | 8.2% | 2.9% |
| NIFTY500 MULTICAP 50:25:25 | 6% | 7.4% | 3.4% |
You may also like the below Video Courses
FAQ about JUBILANT PHARMOVA Financials
How the annual revenues of JUBILANT PHARMOVA have changed ?
The Revenues of JUBILANT PHARMOVA have increased by 2.47% YoY .
How the Earnings per Share (EPS) of JUBILANT PHARMOVA have changed?
The Earnings Per Share (EPS) of JUBILANT PHARMOVA has increased by Positive YoY .
Check out Intrinsic Value of Peers of JUBILANT PHARMOVA
Compare Stock Analytics of Peers of JUBILANT PHARMOVA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
